Cargando…

Elraglusib (formerly 9-ING-41) possesses potent anti-lymphoma properties which cannot be attributed to GSK3 inhibition

Elraglusib (formerly 9-ING-41) is an ATP-competitive inhibitor of glycogen synthase kinase-3β (GSK3β) undergoing clinical trials for the treatment of various cancers including non-Hodgkin lymphoma (NHL). The drug reduces proliferation of several NHL cell lines and has efficacy in xenograft models of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Coats, Josh T., Tauro, Sudhir, Sutherland, Calum
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265916/ https://www.ncbi.nlm.nih.gov/pubmed/37316860 http://dx.doi.org/10.1186/s12964-023-01147-8

Ejemplares similares

Elraglusib (9-ING-41), a selective small-molecule inhibitor of glycogen synthase kinase-3 beta, reduces expression of immune checkpoint molecules PD-1, TIGIT and LAG-3 and enhances CD8(+) T cell cytolytic killing of melanoma cells
por: Shaw, Gary, et al.
Publicado: (2022)

GSK-3β in Pancreatic Cancer: Spotlight on 9-ING-41, Its Therapeutic Potential and Immune Modulatory Properties
por: Park, Robin, et al.
Publicado: (2021)

9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer
por: Kuroki, Hiroo, et al.
Publicado: (2019)

9-ING-41, a Small Molecule Inhibitor of GSK-3β, Potentiates the Effects of Chemotherapy on Colorectal Cancer Cells
por: Poloznikov, Andrey, et al.
Publicado: (2021)

Combination Treatment with the GSK-3 Inhibitor 9-ING-41 and CCNU Cures Orthotopic Chemoresistant Glioblastoma in Patient-Derived Xenograft Models()()
por: Ugolkov, Andrey, et al.
Publicado: (2017)

GSK-3 inhibitor elraglusib enhances tumor-infiltrating immune cell activation in tumor biopsies and synergizes with anti-PD-L1 in a murine model of colorectal cancer
por: Huntington, Kelsey E., et al.
Publicado: (2023)

GSK-3 Inhibitor Elraglusib Enhances Tumor-Infiltrating Immune Cell Activation in Tumor Biopsies and Synergizes with Anti-PD-L1 in a Murine Model of Colorectal Cancer
por: Huntington, Kelsey E., et al.
Publicado: (2023)

Clinically relevant GSK-3β inhibitor 9-ING-41 is active as a single agent and in combination with other antitumor therapies in human renal cancer
por: Anraku, Tsutomu, et al.
Publicado: (2020)

What Are the bona fide GSK3 Substrates?
por: Sutherland, Calum
Publicado: (2011)

Once-daily S/GSK1349572 combination therapy in antiretroviral-naïve adults: rapid and potent 24-week antiviral responses in SPRING-1 (ING112276)
por: Rockstroh, J, et al.
Publicado: (2010)

Malignant glioma subset from actuate 1801: Phase I/II study of 9-ING-41, GSK-3β inhibitor, monotherapy or combined with chemotherapy for refractory malignancies
por: Odia, Yazmin, et al.
Publicado: (2022)

GSK-3β inhibitor, 9-ING-41, reduces cell viability and halts proliferation of B-cell lymphoma cell lines as a single agent and in combination with novel agents
por: Karmali, Reem, et al.
Publicado: (2017)

Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in refractory adult T-Cell leukemia/lymphoma
por: Hsu, Andrew, et al.
Publicado: (2022)

Nrf2 is controlled by two distinct β-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity.
por: Chowdhry, Sudhir, et al.
Publicado: (2012)

A partnership with the proteasome; the destructive nature of GSK3
por: Robertson, Holly, et al.
Publicado: (2018)

Glycogen Synthase Kinase-3β Inhibition with 9-ING-41 Attenuates the Progression of Pulmonary Fibrosis
por: Jeffers, Ann, et al.
Publicado: (2019)

Design and Synthesis of Novel Imidazole Derivatives Possessing Triazole Pharmacophore with Potent Anticancer Activity, and In Silico ADMET with GSK-3β Molecular Docking Investigations
por: Al-blewi, Fawzia, et al.
Publicado: (2021)

Archibald Inglis
Publicado: (1889)

Mallet-ing
Publicado: (1860)

Inge Borghuis
por: Kiers, Bart
Publicado: (2020)

Re-caching by Western Scrub-Jays (Aphelocoma californica) Cannot Be Attributed to Stress
por: Thom, James M., et al.
Publicado: (2013)

Inge J. Lissajoux
Publicado: (2016)

Orbit(ing) the furrow
por: Sreenivasan, Aparna
Publicado: (2004)

SNP'ing for longevity
por: Vijg, Jan
Publicado: (2009)

Check'-ing DLBCL
por: Salaverria, Itziar, et al.
Publicado: (2015)

Elsie Maud Inglis
por: Russell, Beatrice
Publicado: (1918)

David Wood Inglis
Publicado: (1934)

Professor Inglis of Aberdeen
Publicado: (1875)

Sociodemographic Attributes and Prevalence of Arrest With Possession of Substances in Incarcerated Population in the United States
por: Gill, Manpreet, et al.
Publicado: (2022)

Co-expression of adjacent genes in yeast cannot be simply attributed to shared regulatory system
por: Tsai, Huai-Kuang, et al.
Publicado: (2007)

Activity of the integrase inhibitor S/GSK1349572 in subjects with HIV exhibiting raltegravir resistance: week 24 results of the VIKING study (ING112961)
por: Eron, J, et al.
Publicado: (2010)

FRET-ing over scaffolds
por: LeBrasseur, Nicole
Publicado: (2003)

Gett(er)ing to nothing
por: Benvenuti, Cristoforo
Publicado: (2004)

Spy'ing on differentiation in neuroblastoma
por: Podkowa, Monika, et al.
Publicado: (2014)

STIR(ing) appearance of rhabdomyolysis
por: Chakera, Aron, et al.
Publicado: (2008)

Captain Robert Inglis Binning
Publicado: (1916)

"T-bet"-ing on autoimmunity variants
por: Nguyen, Michelle L. T., et al.
Publicado: (2017)

Biological Functions of the ING Proteins
por: Dantas, Arthur, et al.
Publicado: (2019)

Fish-Ing for Enhancers in the Heart
por: Parisi, Costantino, et al.
Publicado: (2021)

Un-“Mask”-ing the leak
por: Iyer, Karthik V., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3s8lijpjbituq0k3ce54h78753